Barcoded viral tracing identifies immunosuppressive astrocyte-glioma interactions

  • Nature. 2025 Jun 25. doi: 10.1038/s41586-025-09191-9.
Brian M Andersen  #  1  2 ,  Camilo Faust Akl  #  1  3 ,  Michael A Wheeler  1  4  5 ,  Zhaorong Li  1 ,  Martin Diebold  6 ,  Michael Kilian  1 ,  Joseph M Rone  1  5 ,  Aditya Misra  5  7  8 ,  Jessica E Kenison  1 ,  Joon-Hyuk Lee  1 ,  Hong-Gyun Lee  1 ,  Carolina M Polonio  1 ,  David Merrell  4 ,  Jakob H Weiss  4 ,  Lillie Godinez  1 ,  Gavin Piester  1 ,  Tomer Illouz  1 ,  Jessica J Ye  1 ,  Arianna Ghia  1 ,  Jazmin Martinez  1 ,  Elizabeth N Chung  1 ,  Lena Srun  1 ,  Daniel Farrenkopf  1 ,  Lucas E Flausino  1 ,  Anton M Schüle  1 ,  Liliana M Sanmarco  1 ,  Federico Giovannoni  1 ,  Luca Fehrenbacher  6 ,  Marc Charabati  1 ,  Cristina Gutiérrez-Vázquez  1 ,  Margaret M Cusick  8  9 ,  Prem S Prabhakar  8  9 ,  Connor C Bossi  8  9 ,  Emily Lapinskas  8  9 ,  Roni Nowarski  1  4  5 ,  Gad Getz  4  10 ,  Keith L Ligon  8  9 ,  Marco Prinz  6  11 ,  E Antonio Chiocca  12 ,  David A Reardon  13 ,  Francisco J Quintana  14  15  16
Affiliations
  • 1. Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • 2. Department of Neurology, Veterans Affairs Medical Center, Harvard Medical School, Jamaica Plain, MA, USA.
  • 3. Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • 4. Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • 5. The Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • 6. Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • 7. Harvard-MIT Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • 8. Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • 9. Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • 10. Department of Pathology and Krantz Family Center for Cancer Research, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
  • 11. Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
  • 12. Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • 13. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • 14. Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. [email protected].
  • 15. Broad Institute of MIT and Harvard, Cambridge, MA, USA. [email protected].
  • 16. The Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. [email protected].
  • # Contributed equally.
Abstract

Glioblastoma (GBM) is the most lethal primary brain malignancy1. Immunosuppression in the GBM tumour microenvironment (TME) is an important barrier to immune-targeted therapies, but our understanding of the mechanisms of immune regulation in the GBM TME is limited2. Here we describe a viral barcode interaction-tracing approach3 to analyse TME cell-cell communication in GBM clinical samples and preclinical models at single-cell resolution. We combine it with single-cell and bulk RNA-sequencing analyses, human organotypic GBM cultures, in vivo cell-specific CRISPR-Cas9-driven genetic perturbations as well as human and mouse experimental systems to identify an annexin A1-formyl peptide receptor 1 (ANXA1-FPR1) bidirectional astrocyte-GBM communication pathway that limits tumour-specific immunity. FPR1 inhibits immunogenic Necroptosis in tumour cells, and AnxA1 suppresses NF-κB and inflammasome activation in astrocytes. AnxA1 expression in astrocytes and FPR1 expression in Cancer cells are associated with poor outcomes in individuals with GBM. The inactivation of astrocyte-glioma ANXA1-FPR1 signalling enhanced dendritic cell, T cell and macrophage responses, increasing infiltration by tumour-specific CD8+ T cells and limiting T cell exhaustion. In summary, we have developed a method to analyse TME cell-cell interactions at single-cell resolution in clinical samples and preclinical models, and used it to identify bidirectional astrocyte-GBM communication through ANXA1-FPR1 as a driver of immune evasion and tumour progression.

Products